- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01084876
Demonstrate Efficacy and Safety of Metastatic Breast Cancer (Compare)
February 11, 2015 updated by: Celltrion
Double-blind, Randomised, Parallel Group, Phase III Study
The purpose of the study is to to demonstrate equivalence
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Patients will receive study drug every 3 weeks.
Study Type
Interventional
Enrollment (Actual)
383
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Baia-mare, Romania
- Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Are females
- Have a Her 2 over-expression
- Have ECOG 0 or 1
Exclusion Criteria:
- Current clinical or radiographic evidence CNS metastases
- Current Known infection
- Pregnant or nursing mother
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: CT-P6 & Paclitaxel
CT-P6 + Paclitaxel
|
Administered every 3 weeks
Administered every 3weeks
|
Active Comparator: Herceptin & Paclitaxel
Trastuzumab + Paclitaxel
|
Administered every 3weeks
Administered every 3 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To Compare Efficacy
Time Frame: months
|
months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
efficacy and safety
Time Frame: months
|
months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Investigational Site, Samsung Medical Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2010
Primary Completion (Actual)
December 1, 2011
Study Completion (Anticipated)
December 1, 2017
Study Registration Dates
First Submitted
March 9, 2010
First Submitted That Met QC Criteria
March 9, 2010
First Posted (Estimate)
March 11, 2010
Study Record Updates
Last Update Posted (Estimate)
February 12, 2015
Last Update Submitted That Met QC Criteria
February 11, 2015
Last Verified
February 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CT-P6/3.1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Breast Cancer
-
Gilead SciencesRecruitingStudy of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors (ASCENT-J02)Advanced Solid Tumor | Metastatic Urothelial Cancer | Metastatic Triple-Negative Breast Cancer | HR+/HER2- Metastatic Breast CancerJapan
-
GlycoMimetics IncorporatedTerminatedBreast Cancer | Breast Cancer Metastatic | HR+ Metastatic Breast CancerUnited States
-
BriaCell Therapeutics CorporationRecruitingBreast Cancer | Breast Neoplasm | Metastatic Breast Cancer | Breast Cancer Metastatic | End Stage CancerUnited States
-
OBI Pharma, IncCompletedMetastatic Colorectal Cancer | Metastatic Lung Cancer | Metastatic Breast Cancer | Metastatic Gastric CancerTaiwan
-
Massachusetts General HospitalPuma Biotechnology, Inc.; Celcuity, Inc.WithdrawnMetastatic Breast Cancer | Invasive Breast Cancer | HER2-negative Breast Cancer | ER Positive Breast Cancer | PR-Positive Breast Cancer | Stage IV (Metastatic) Breast CancerUnited States
-
Novartis PharmaceuticalsCompletedMetastatic Breast Cancer | Postmenopausal Women | Locally Advanced Metastatic Breast CancerIsrael
-
Institut de Recherches Internationales ServierADIR, a Servier Group companyCompletedMetastatic Breast Cancer | Metastatic Triple Negative Breast CancerJapan, Belgium, France, Netherlands
-
BriaCell Therapeutics CorporationLumaBridgeEnrolling by invitationBreast Cancer | Breast Neoplasm | Metastatic Breast Cancer | Breast Cancer MetastaticUnited States
-
Prof. Wolfgang JanniEli Lilly and CompanyRecruitingHormone Receptor-positive Metastatic Breast Cancer | HER2-negative Metastatic Breast CancerGermany, Switzerland
-
Hoffmann-La RocheCompletedHER2-Positive Metastatic Breast Cancer | HER2-Negative Metastatic Breast Cancer | Locally Advanced or Early Breast CancerUnited States
Clinical Trials on CT-P6
-
Northwestern UniversityCompleted
-
Northwestern UniversityCompletedNausea | Vomiting | Pregnancy Related | Cesarean DeliveryUnited States
-
LISCure BiosciencesCompletedRheumatoid Arthritis | Non-Alcoholic SteatohepatitisAustralia
-
CelltrionUnknownMetastatic Breast CancerKorea, Republic of
-
National Cancer Institute (NCI)NRG OncologyActive, not recruitingBreast Ductal Carcinoma In SituUnited States, Canada, Puerto Rico, Korea, Republic of
-
Umeå UniversityCompletedPostoperative Nausea and Vomiting | Craniotomy | AcupressureSweden
-
Milliken Healthcare Products, LLCU.S. Army Medical Research and Development Command; Criterium, Inc.CompletedBurns | Skin Burn Requiring Skin GraftUnited States
-
Beijing University of Chinese MedicineGuang'anmen Hospital of China Academy of Chinese Medical Sciences; Xiyuan Hospital... and other collaboratorsCompletedChemotherapy-induced Nausea and VomitingChina
-
CelltrionCompleted
-
University of PittsburghTerminatedCarcinoma, Squamous Cell of Head and NeckUnited States